CVS Health (NYSE:CVS – Get Free Report)‘s stock had its “neutral” rating reissued by analysts at Cantor Fitzgerald in a report issued on Tuesday, Benzinga reports. They currently have a $62.00 price target on the pharmacy operator’s stock. Cantor Fitzgerald’s target price points to a potential downside of 0.39% from the company’s current price.
A number of other research firms have also recently issued reports on CVS. Deutsche Bank Aktiengesellschaft dropped their price target on shares of CVS Health from $64.00 to $63.00 and set a “hold” rating on the stock in a research note on Friday, August 9th. Evercore ISI cut their target price on shares of CVS Health from $65.00 to $62.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Barclays decreased their price target on shares of CVS Health from $65.00 to $63.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 8th. Wells Fargo & Company boosted their price objective on CVS Health from $60.00 to $61.00 and gave the stock an “equal weight” rating in a research note on Monday, August 12th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $68.00 target price on shares of CVS Health in a research report on Wednesday, September 4th. Eleven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, CVS Health currently has an average rating of “Moderate Buy” and a consensus target price of $72.10.
Get Our Latest Stock Analysis on CVS Health
CVS Health Stock Performance
CVS Health (NYSE:CVS – Get Free Report) last posted its earnings results on Wednesday, August 7th. The pharmacy operator reported $1.83 EPS for the quarter, beating analysts’ consensus estimates of $1.73 by $0.10. The firm had revenue of $91.23 billion for the quarter, compared to analysts’ expectations of $91.41 billion. CVS Health had a return on equity of 12.72% and a net margin of 1.98%. The company’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period last year, the firm earned $2.21 EPS. On average, research analysts predict that CVS Health will post 6.51 earnings per share for the current year.
Institutional Trading of CVS Health
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Ables Iannone Moore & Associates Inc. purchased a new position in CVS Health during the fourth quarter worth about $32,000. First Community Trust NA increased its holdings in CVS Health by 116.2% in the 2nd quarter. First Community Trust NA now owns 562 shares of the pharmacy operator’s stock valued at $33,000 after purchasing an additional 302 shares during the last quarter. Creekmur Asset Management LLC purchased a new stake in CVS Health in the fourth quarter valued at approximately $34,000. Steph & Co. lifted its stake in CVS Health by 192.0% during the first quarter. Steph & Co. now owns 438 shares of the pharmacy operator’s stock worth $35,000 after purchasing an additional 288 shares in the last quarter. Finally, ORG Partners LLC boosted its position in shares of CVS Health by 11,840.0% during the second quarter. ORG Partners LLC now owns 597 shares of the pharmacy operator’s stock worth $35,000 after buying an additional 592 shares during the period. 80.66% of the stock is owned by institutional investors and hedge funds.
CVS Health Company Profile
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
See Also
- Five stocks we like better than CVS Health
- Upcoming IPO Stock Lockup Period, Explained
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- The 3 Best Fintech Stocks to Buy Now
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- What is a Death Cross in Stocks?
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.